Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator Group.
A multicenter prospective study was carried out to evaluate whether a vapor-heated factor VIII concentrate transmitted blood-borne viral infections over a surveillance period of 15 months. Thirty-five patients with hemophilia and von Willebrand disease who had never received any blood components were treated. Twenty-eight were analyzed and found not to have non-A, non-B hepatitis. Sera from 20 of these 28 patients were also tested for the antibody to the hepatitis C virus. None had sero-converted during the follow-up period. None of the patients analyzed developed markers of the hepatitis B virus (n = 17) or the human immunodeficiency virus (n = 31). This vapor-heated factor VIII concentrate carries a low risk of transmitting hepatitis and human immunodeficiency virus infection.
Mannucci
P M
PM
Centro Emofilia e Trombosi Angelo Bianchi Bonomi, Milan, Italy.
Schimpf
K
K
Abe
T
T
Aledort
L M
LM
Anderle
K
K
Brettler
D B
DB
Hilgartner
M W
MW
Kernoff
P B
PB
Kunschak
M
M
McMillan
C W
CW
D001803:Blood Transfusion; D002648:Child; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000209:etiology; D005169:Factor VIII / Q000627:therapeutic use*; D005500:Follow-Up Studies; D015658:HIV Infections / Q000175:diagnosis / Q000209:etiology; D006467:Hemophilia A / Q000628:therapy*; D006509:Hepatitis B / Q000175:diagnosis / Q000209:etiology; D006526:Hepatitis C / Q000175:diagnosis / Q000209:etiology; D006358:Hot Temperature; D006801:Humans; D011446:Prospective Studies; D014777:Virus Diseases / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D014842:von Willebrand Diseases / Q000628:therapy*
D005169:Factor VIII